This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): darunavir, TMC114
Description: Prezista is a protease inhibitor that is highly active in vitro against HIV with PI resistance mutations and against PI-resistant clinical isolates.
Deal Structure: Prezista was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products. Ortho Biotech Products is a wholly owned subsidiary of Johnson & Johnson. In the European Union, Russia, Switzerland and other countries, Prezista is marketed by Tibotec, a division of Janssen-Cilag. In Canada, PREZISTA is marketed by Tibotec, a division of Janssen-Ortho.
Aspen and Tibotec
In April 2007, Tibotec announced that it signed a royalty-free, non-exclusive license agreement with Aspen of South Africa. Aspen will register, package and distribute PREZISTA in sub-Saharan Africa.
Emcure and Tibotec
In December 2008, Tibotec announced that it signed a royalty-free, non-exclusive license agreement with Emcure Pharmaceuticals to distribute darunavir in India.
Pink Sheet Prezista FDA Reviewers
Pink Sheet Prezista Clinical Development
Additional information available to subscribers only: